Hereditary Angioedema: A Clinical Overview
Written by Margaret Anne Rockwood | Last updated September 4th, 2026
Medically reviewed by Timothy J. Craig, DO
Hereditary angioedema (HAE) is a rare, autosomal dominant disorder characterized by recurrent episodes of nonpruritic, nonpitting edema involving the skin, gastrointestinal tract, and upper airway.
Unlike histamine-mediated angioedema, most forms of HAE are bradykinin-mediated, arising from dysregulation of the contact/kallikrein-kinin system or related pathways controlling vascular permeability. As such, conventional therapies for histamine-mediated angioedema, such as antihistamines, corticosteroids, and epinephrine, are ineffective.
Although targeted therapies have substantially improved outcomes, delays in diagnosis remain common, contributing to avoidable morbidity, diminished quality of life (QoL), and, in some cases, fatal laryngeal attacks.
Epidemiology
The prevalence of HAE in both the United States and worldwide is estimated to be 1.70 per 100,000 individuals. The disorder affects individuals across all racial and ethnic groups and geographic regions, without significant clustering patterns or a preponderance in any particular population.
According to the latest WAO/EAACI guideline for the management of HAE, key epidemiological features may include:
- Inheritance: Autosomal dominant; 75% of patients inherit HAE from an affected parent
- De novo mutations: Approximately 20% to 25% of cases arise from spontaneous pathogenic variants
- Sex distribution: Males and females are affected with similar frequency, although women often experience more attacks and more severe disease because of estrogen-mediated effects on bradykinin production
- Age of onset: Most patients develop symptoms during childhood or adolescence; onset around age 10 to 11 years has been reported in large cohorts.
- Age of diagnosis: Despite earlier symptom onset, diagnosis is frequently delayed by 8 to 20 years, particularly among patients without a recognized family history.
Disease severity varies considerably, even among affected members of the same family. Attacks can range from none to a few annually to weekly or more frequent episodes, the latter of which can substantially impair daily functioning.
Pathophysiology
Hereditary angioedema is caused by excessive production of bradykinin, a small peptide that acts as a potent vasoactive agent, increasing vascular permeability and promoting leakage from the blood vessels into local tissues. When this occurs and is unchecked by other mechanisms, angioedema follows.
In approximately 85% of people with HAE, the disease origin is a genetically driven deficiency or dysfunction of C1 esterase inhibitors (C1-INH). These inhibitors are key to regulating several plasma protease systems, including the complement, contact, coagulation, and fibrinolytic pathways. These systems serve as a “check” on activated plasma kallikrein and coagulation factor XIIa, which are responsible for the generation of bradykinin.
When C1-INH is deficient or dysfunctional, unchecked activation of kallikrein and factor XIIa create excessive cleavage of high-molecular-weight kininogen, which can lead to overproduction of bradykinin. Bradykinin binds endothelial B2 receptors, responsible for opening endothelial junctions (see Figure 1).
Figure 1.
Genetic mutation
↓
C1 esterase inhibitor (C1-INH) deficient or dysfunctional
↓
Loss of inhibition of Factor XIIa & plasma kallikrein
↓
Excess cleavage of high-molecular-weight kininogen (HMWK)
↓
Excess bradykinin production
↓
Bradykinin binds with endothelial B2 receptors
↓ ↑
Vascular permeability (leaky blood vessels)
↓
Fluid leaks into tissues
↓
Swelling (angioedema)
Genetic Roots and Subtypes
The genes responsible for HAE may be pathogenic variants of SERPING1, F12, PLG, and ANGPT1. The majority (approximately 85% to 90%) are related to the SERPING1 gene, which encodes C1 esterase inhibitor (C1-INH).
Current HAE classification recognizes several forms, as outlined in Table I.
Table I: Hereditary Angioedema Subtypes.
Scroll horizontally to view all columns -->
|
HAE subtype |
Underlying defect |
Prevalence |
| Type I | Low C1-INH protein level and function | ~85% of cases |
| Type II | Normal or elevated C1-INH level, but with reduced function | ~15% of cases |
| HAE with normal C1-INH (HAE-nC1INH) | Normal C1-INH level and function, but other factors influencing bradykinin production OR abnormal vessel responses to vasodilation (F12, PLG, ANGPT1, KNG1, MYOF, HS3ST6, and others). | Rare |
.bio-table-responsive{overflow-x:auto;max-width:100%;border:1px solid #ccc}.bio-table-block table{border-collapse:collapse;min-width:600px;width:100%}.bio-table-block th,.bio-table-block td{padding:.6rem;border:1px solid #ccc;text-align:left;vertical-align:top;word-break:break-word}.bio-table-block thead th{background:#eee;position:sticky;top:0}.bio-table-scroll-hint{display:none;font-size:.9rem;margin-bottom:.4rem;color:#555}@media (max-width:640px){.bio-table-scroll-hint{display:block}}In type I and type II HAE, the pathogenic mechanisms responsible for angioedema attacks are related to excessive bradykinin generation. Some rare mutations also appear to increase generation of bradykinin (especially F12 and probably PLG/KNG1-related disease).
Among the genetically defined forms of HAE with normal C1-INH, F12-associated HAE is one of the better-characterized subtypes. F12-associated HAE results from gain-of-function variants in factor XII that enhance activation of the kallikrein-kinin system, ultimately increasing bradykinin generation.
HAE can be more severe in females because estrogen promotes bradykinin production by multiple mechanisms, including increasing factor XII activation. Attacks often worsen during pregnancy and with use of estrogen-containing contraceptives or hormone replacement therapy.
In some rare subtypes, however, angioedema may derive from altered endothelial barrier regulation or the vessel’s response to permeability signals rather than bradykinin overproduction.
Quality of Life
The burden of HAE extends beyond episodic swelling. Patients often experience chronic anxiety related to the unpredictability of attacks, fear of airway compromise, impaired school or work productivity, and reduced participation in social and physical activities. Frequent emergency department visits, hospitalizations, and diagnostic uncertainty further contribute to disease burden.
Studies consistently demonstrate impaired health-related QoL among patients with inadequately controlled HAE, underscoring the importance of early diagnosis and individualized management.
Sources
- Bernstein JA. Severity of hereditary angioedema, prevalence, and diagnostic considerations. Am J Manag Care. 2018;24(14 Suppl):S292-S298.
- Bork K, Machnig T, Wulff K, Witzke G, Prusty S, Hardt J. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15:289. doi:10.1186/s13023-020-01570-x
- Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382(12):1136-1148. doi:10.1056/NEJMra1808012
- Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046
- Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(3):193-204. doi:10.1016/j.anai.2010.01.007
- Levy DS, Nagase FI, Cheung A, Rodeberg DA, Manning ME. Quality of life and burden of disease in patients with hereditary angioedema and their caregivers. Allergy Asthma Proc. 2025;46(5):398-405. doi:10.2500/aap.2025.46.250035
- Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update. Allergy. 2022;77(7):1961-1990. doi:10.1111/all.15214
- Wedner HJ. Hereditary angioedema: pathophysiology (HAE type I, HAE type II, and HAE nC1-INH). Allergy Asthma Proc. 2020;41(suppl 1):S14-S17. doi:10.2500/aap.2020.41.200082
- Zuraw BL, Christiansen SC. Pathophysiology of hereditary angioedema. Am J Rhinol Allergy. 2011;25(6):373-378. doi:10.2500/ajra.2011.25.3661
- Zuraw BL, Bork K, Bouillet L, Christiansen SC, Farkas H, Germenis AE, et al. Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment. Clin Rev Allergy Immunol. 2025;68(1):24. doi:10.1007/s12016-025-09027-4